Heart Failure

ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.

Finerenone treatment achieved a statistically significant reduction in a composite endpoint of CV death and HF events in a population not limited to CKD in T2D, Bayer announced.

Tirzepatide reduced the risk of severe heart failure outcomes by 38% and drove weight loss of 15.7% in adults with HFpEF and obesity, with and without T2D..

Your daily dose of the clinical news you may have missed.

Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.

Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.

Your daily dose of the clinical news you may have missed.

Patients with HF who received SGLT2i therapy had significant improvement in functional capacity and QOL, regardless of sex, diabetes status, or ejection fraction, report researchers.

The majority of the US adult population meets criteria for subclinical CKM syndrome indicating "an urgent need for population-wide risk reduction measures."

Your daily dose of the clinical news you may have missed.